-
ML385 Workflows for NRF2 Pathway Research
2026-09-24
Use ML385 to test whether NRF2 activity contributes to antioxidant defenses, inflammatory phenotypes, or cancer therapeutic resistance—not simply whether a treatment changes cell viability. This workflow pairs a concentration-and-time pilot with orthogonal pathway readouts and highlights a recent osteoclast study that used ML385 to test NRF2 dependence outside cancer models.
-
TMRE Assays for Sodium-Driven Mitochondrial Failure
2026-09-24
The TMRE mitochondrial membrane potential assay kit can reveal how sodium stress alters mitochondrial polarization—but fluorescence alone cannot identify the cause or type of cell death. This article connects TMRE readouts to recent findings on sodium-driven energy failure and outlines a more defensible experimental strategy.
-
ABT-737 for Mitochondrial Apoptosis Assays
2026-09-23
Use ABT-737 to probe BCL-2-family dependence and apoptosis in cancer models, then pair cell-death measurements with mitochondrial mRNA imaging to ask what changes inside mitochondria. This workflow connects a practical BH3-mimetic perturbation to super-resolution methods while clearly separating established findings from experiments that still need validation.
-
GSTA1 Amplifies α-Amanitin Liver Injury
2026-09-23
This study identifies GSTA1 as an unexpected pathogenic driver in α-amanitin-induced hepatotoxicity rather than a uniformly protective antioxidant enzyme. By combining mouse toxicology, multi-omics, interaction assays, and genetic experiments, the authors link GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte injury.
-
STT3A–FCN3 Glycosylation in HCC Progression
2026-09-22
The reference study identifies an STT3A–FCN3–APC/Wnt/β-catenin pathway linking aberrant N-glycosylation to regulatory T-cell activation and hepatocellular carcinoma progression. Its combination of site-directed glycosylation analysis, genetic perturbation, cell assays, and xenograft experiments provides a framework for distinguishing global glycosylation effects from FCN3-specific mechanisms.
-
Sodium-Driven Mitochondrial Failure in NECSO
2026-09-22
Qiao and colleagues identify mitochondrial energy failure as the mechanistic link between TRPM4-mediated sodium influx and necrosis by sodium overload (NECSO). Their findings connect mitochondrial sodium accumulation, NCLX-dependent calcium loss, impaired oxidative metabolism, ATP depletion, and Na/K-ATPase failure into a coherent pathway that explains cell swelling and lysis.
-
(Z)-4-Hydroxytamoxifen in Relapse Models
2026-09-21
A mechanistic and translational framework for using (Z)-4-Hydroxytamoxifen to interrogate estrogen receptor biology while strategically integrating proliferation-tracing models of breast cancer relapse.
-
How Sodium Overload Executes NECSO
2026-09-21
Qiao and colleagues show that TRPM4-driven sodium entry causes necrosis through mitochondrial energy failure, not simply through osmotic swelling. Sodium accumulation in mitochondria alters NCLX-dependent calcium handling, suppresses oxidative phosphorylation and the TCA cycle, depletes ATP, and ultimately disables Na/K-ATPase-dependent ion homeostasis.
-
RSL3: Translating Ferroptosis Mechanisms
2026-09-20
A thought-leadership guide to using RSL3 as a mechanistic GPX4 probe, validating ferroptosis rigorously, interpreting oncogenic RAS vulnerability, and advancing preclinical findings toward translationally meaningful decisions.
-
D-N-Acetylgalactosamine Workflow Guide
2026-09-19
D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for aqueous or DMSO-based studies of glycoprotein composition, brain heteropolysaccharides, and related glycosylation workflows. It should not be used in ethanol-based preparations or for long-term storage of solutions; prepare working solutions close to use and store the solid at -20°C.
-
Irinotecan Beyond Cytotoxicity: Assay Design
2026-09-18
Irinotecan (CPT-11) is more than a topoisomerase I inhibitor: it can serve as a layered research perturbation linking tumor DNA damage with chemotherapy-associated gut–liver injury. This article translates recent mechanistic evidence into practical assay and workflow decisions for colorectal cancer research.
-
Cy3 NHS ester (non-sulfonated) Workflow Guide
2026-09-18
Cy3 NHS ester (non-sulfonated), SKU A8100, provides an orange fluorescent NHS ester for labeling accessible amino groups in proteins, peptides, and oligonucleotides. It is appropriate when an organic co-solvent is compatible with the biomolecule, but it should not be selected for water-only labeling or long-term storage of prepared dye solutions.
-
CDC42 Polarity Controls Intestinal Stem Cell Fate
2026-09-17
Zhang and colleagues show that CDC42-dependent epithelial polarity regulates the intestinal stem cell to transit-amplifying cell transition through a YAP/TAZ–Ereg–EGFR–mTOR cascade, rather than solely through canonical Wnt signaling. Genetic and pharmacological rescue experiments distinguish restoration of crypt proliferation and cell-fate balance from restoration of epithelial polarity, providing a useful framework for studying intestinal homeostasis.
-
G007-LK Tankyrase 1/2 Inhibitor: Research Workflows
2026-09-17
G007-LK provides a practical route to connect tankyrase enzymatic inhibition with AXIN stabilization, β-catenin degradation, and downstream growth phenotypes. This guide translates those mechanisms into reproducible Wnt reporter, protein, colony-formation, and Hippo pathway workflows for cancer biology research.
-
Topotecan in First-Line Small Cell Lung Cancer
2026-09-16
This reference article examines whether topotecan-based combinations could improve first-line treatment for small cell lung cancer, where initial chemotherapy responses are often followed by relapse and resistance. Its central contribution is a clinically focused synthesis of response and toxicity signals from phase II studies, emphasizing regimen design, reversible neutropenia, and the need for confirmatory trials rather than presenting a definitive practice-changing conclusion.